NASDAQ:CLCD (CLCD) (CLCD) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free CLCD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$46.53▼$46.5350-Day Range N/A52-Week Range$5.26▼$46.65VolumeN/AAverage Volume708,479 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (CLCD) alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About (CLCD) Stock (NASDAQ:CLCD)CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.Read More Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. CLCD Stock News HeadlinesFebruary 21, 2024 | au.finance.yahoo.comCalculus VCT plc (CLCD.L)November 10, 2023 | msn.comSix Signs Of Liver Disease - What Are The Signs & Symptoms Indicate That You Have Liver DiseaseApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. September 13, 2023 | msn.comGoogle Cloud to verify messages sent between blockchains in agreement with $3 billion startup LayerZeroJuly 7, 2023 | msn.comRooftop fire at St. Cloud's convention center causes at least $200,000 in damageJune 20, 2023 | msn.comLionel Messi’s reunion in Inter Miami with ex-Barcelona teammates gets huge updateJune 10, 2023 | msn.comPhil Neville hired for Canada staff after Inter Miami departureJune 9, 2023 | msn.comMike’s Place in Kenilworth Specials of the Day June 9April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. June 9, 2023 | msn.comHere's the Rolex given to winners of this weekend's Le Mans 24hrJune 1, 2023 | benzinga.comDr. Robert Harrington named dean of Weill Cornell MedicineApril 10, 2023 | msn.comReform rote education to address 21st Century problems – Prof OwusuApril 8, 2023 | msn.comSoccer-Lazio beat Juve 2-1 to cement second placeMarch 29, 2023 | msn.comYes, that's Luke Skywalker on a Ukrainian air-raid appMarch 29, 2023 | msn.comCOVID Cases Today: India records 2,151 new cases, highest in 5 months; 7 fatalitiesMarch 3, 2023 | msn.comHow Deem Spencer Learned to be Vulnerable on His New Album ‘adultSW!M’February 4, 2023 | msn.comCLCD explores Peer Health Navigators programme with caregivers.January 22, 2023 | msn.comThe Best Fictional Planets In TV ShowsJanuary 22, 2023 | msn.comAthletic Club v Real Madrid - How To Watch, TV Channel, Live Stream DetailsNovember 17, 2022 | msn.comMan arrested for Danville parking lot shootingNovember 17, 2022 | msn.comMan treated after being shot in Danville parking lotNovember 17, 2022 | msn.comMan treated after being shot in parking lotNovember 2, 2022 | msn.comUPDATE 7-Takeoff of rap group Migos shot dead at Houston partyNovember 1, 2022 | msn.comUPDATE 6-Takeoff of the rap group Migos shot to death at Houston partyNovember 1, 2022 | msn.comUPDATE 5-Rapper Takeoff killed in Houston shooting, attorney saysSeptember 15, 2022 | thestreet.comStock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading BoostSeptember 8, 2022 | msn.comFormula 1 Pays Tribute to Her Majesty, Queen Elizabeth IISee More Headlines Receive CLCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (CLCD) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2016Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CLCD CUSIPN/A CIK1348649 Webwww.colucid.com Phone+1-781-3652596FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report CLCD Stock Analysis - Frequently Asked Questions How were (CLCD)'s earnings last quarter? (CLCD) (NASDAQ:CLCD) released its quarterly earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.79). What other stocks do shareholders of (CLCD) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (CLCD) investors own include Gilead Sciences (GILD), (KITE) (KITE), Dova Pharmaceuticals (DOVA), OPKO Health (OPK), Novavax (NVAX), Block (SQ), Ariad Pharmaceuticals (ARIA), Bausch Health Companies (BHC), Biopharmx (BPMX) and When did (CLCD) IPO? (CLCD) (CLCD) raised $55 million in an initial public offering on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and William Blair was co-manager. This page (NASDAQ:CLCD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (CLCD) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
